1552 related articles for article (PubMed ID: 18156464)
41. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
[TBL] [Abstract][Full Text] [Related]
42. APP processing is regulated by cytoplasmic phosphorylation.
Lee MS; Kao SC; Lemere CA; Xia W; Tseng HC; Zhou Y; Neve R; Ahlijanian MK; Tsai LH
J Cell Biol; 2003 Oct; 163(1):83-95. PubMed ID: 14557249
[TBL] [Abstract][Full Text] [Related]
43. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
Hook VY; Reisine TD
J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
[TBL] [Abstract][Full Text] [Related]
44. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation.
Jäger S; Leuchtenberger S; Martin A; Czirr E; Wesselowski J; Dieckmann M; Waldron E; Korth C; Koo EH; Heneka M; Weggen S; Pietrzik CU
J Neurochem; 2009 Dec; 111(6):1369-82. PubMed ID: 19804379
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
46. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
Nawrot B
Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
[TBL] [Abstract][Full Text] [Related]
47. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
[TBL] [Abstract][Full Text] [Related]
48. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.
Farzan M; Schnitzler CE; Vasilieva N; Leung D; Choe H
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9712-7. PubMed ID: 10931940
[TBL] [Abstract][Full Text] [Related]
49. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
50. Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling.
Shimazawa M; Inokuchi Y; Okuno T; Nakajima Y; Sakaguchi G; Kato A; Oku H; Sugiyama T; Kudo T; Ikeda T; Takeda M; Hara H
J Neurochem; 2008 Oct; 107(1):279-90. PubMed ID: 18691390
[TBL] [Abstract][Full Text] [Related]
51. BACE (beta-secretase) modulates the processing of APLP2 in vivo.
Pastorino L; Ikin AF; Lamprianou S; Vacaresse N; Revelli JP; Platt K; Paganetti P; Mathews PM; Harroch S; Buxbaum JD
Mol Cell Neurosci; 2004 Apr; 25(4):642-9. PubMed ID: 15080893
[TBL] [Abstract][Full Text] [Related]
52. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
53. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
Züchner T; Perez-Polo JR; Schliebs R
J Neurosci Res; 2004 Jul; 77(2):250-7. PubMed ID: 15211591
[TBL] [Abstract][Full Text] [Related]
54. Bace1 modulates myelination in the central and peripheral nervous system.
Hu X; Hicks CW; He W; Wong P; Macklin WB; Trapp BD; Yan R
Nat Neurosci; 2006 Dec; 9(12):1520-5. PubMed ID: 17099708
[TBL] [Abstract][Full Text] [Related]
55. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
56. Effect of heparin on APP metabolism and Abeta production in cortical neurons.
Klaver D; Hung AC; Gasperini R; Foa L; Aguilar MI; Small DH
Neurodegener Dis; 2010; 7(1-3):187-9. PubMed ID: 20224283
[TBL] [Abstract][Full Text] [Related]
57. Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells.
Li Q; Wu D; Zhang L; Zhang Y
Exp Gerontol; 2010 Nov; 45(11):842-7. PubMed ID: 20600777
[TBL] [Abstract][Full Text] [Related]
58. Amyloid-β₄₂ activates the expression of BACE1 through the JNK pathway.
Guglielmotto M; Monteleone D; Giliberto L; Fornaro M; Borghi R; Tamagno E; Tabaton M
J Alzheimers Dis; 2011; 27(4):871-83. PubMed ID: 21897006
[TBL] [Abstract][Full Text] [Related]
59. Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells.
Esposito L; Gan L; Yu GQ; Essrich C; Mucke L
J Neurochem; 2004 Dec; 91(6):1260-74. PubMed ID: 15584903
[TBL] [Abstract][Full Text] [Related]
60. BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice.
Herzig MC; Paganetti P; Staufenbiel M; Jucker M
Neurodegener Dis; 2007; 4(2-3):127-35. PubMed ID: 17596707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
